Federation Des Caisses Desjardins Du Quebec Equillium, Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

$17.5 Billion
Q2 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2020 Aug 30, 2024	SELL	$3.48 - $6.58 $3,480 - $6,580	-1,000 Closed	0 $0
Q3 2020 Aug 30, 2024	BUY	$2.78 - $26.5 $2,780 - $26,500	1,000 New	1,000 $5.77 Million

Others Institutions Holding EQ

# of Institutions

Shares Held

11.5M

Call Options Held

38.1K

Put Options Held

Decheng Capital LLC Menlo Park, CA

4.45M
Shares

$3.82 Million
0.94% of portfolio
Decheng Capital Management Iii (Cayman), LLC

4.45M
Shares

$3.82 Million
1.82% of portfolio
Vanguard Group Inc Valley Forge, PA

842K
Shares

$724,075
0.0% of portfolio
Cota Capital Management, LLC San Francisco, CA

562K
Shares

$483,559
1.37% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

300K
Shares

$258,344
0.0% of portfolio

View Full List

About Equillium, Inc.

Ticker EQ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,352,100
Market Cap $29.5M
Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...

More about EQ

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account